Articles tagged with Effector T Cells
A new study from the University of Lausanne identifies a specific subset of fibroblasts that produce Ccl19, an 'attractant signal' for cytotoxic T lymphocytes, bringing them into contact with type 1 dendritic cells. This mechanism is essential for proper immune cell organization and function.
Researchers reveal that immune system's T cells travel to the prostate to provide long-term protection against infections. Harnessing these disease-fighting cells could lead to new therapies for prostate cancer and inflammatory conditions.
Researchers at La Jolla Institute for Immunology discovered that ALS is likely caused by an autoimmune reaction triggered by inflammatory CD4+ T cells targeting specific proteins in the nervous system. Anti-inflammatory CD4+ T cells may slow disease progression and prolong survival times.
Researchers discovered that immune cells called T cells are abundant in mammary glands during pregnancy and breastfeeding, with some relocating from the gut. This finding may help explain the benefits of breastfeeding and inform dietary decisions to enhance breast milk production and quality.
Researchers at La Jolla Institute for Immunology discovered that CD4+ T cells target Chikungunya virus, leading to chronic inflammation and joint pain. The study suggests that these monofunctional T cells may be the culprits behind arthritis-like symptoms in CHIKV patients.
This study explored the immune dynamics across different phases of HBV infection, identifying key factors influencing T cell function and liver priming. The research team uncovered distinct types of intrahepatic T lymphocytes and dual roles of DC-SIGN+ macrophages in modulating immune responses.
Researchers have elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune responses. PP2A deficiency impairs T cell effector functions, leading to reduced cytokine production and impaired antiviral responses.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
Researchers at La Jolla Institute for Immunology discovered that tissue-resident memory CD8 T cells rise up to fight infections in the small intestine, using spatial transcriptomics technology. These immune cells are split between villi and crypts, with progenitor-like cells replenishing effector T cells.
Researchers at Salk Institute establish a novel framework for the relationship between nutrition and cell identity. They found that a nutritional switch from acetate to citrate plays a key role in determining T cell fates, shifting them from active effector cells to exhausted cells.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
Researchers at POSTECH have identified GLUT3 as essential for the suppressive function of regulatory T cells in tumor microenvironments, which can be targeted for cancer immunotherapy. The team's findings highlight the critical role of GLUT3 in regulating protein modifications that sustain immune suppression within tumors.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
Researchers found that fever temperatures increase helper T cell metabolism, proliferation and inflammatory activity, while causing mitochondrial stress, DNA damage and cell death in a specific subset of Th1 cells. These findings may explain how chronic inflammation contributes to cancer development and suggest a fundamental way cells ...
CAR-Enhancer therapy boosts CAR T cells' activity and persistence, enabling them to remain in battle mode until all tumor cells are eliminated. The treatment also fosters a memory of cancer cells, allowing the CAR T cells to spring back into action upon recurrence.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Researchers at St. Jude Children's Research Hospital found that a 'Goldilocks' binding strength between T-cell receptors and cancer proteins determines anti-cancer T-cell efficacy. The optimal middle-ground binding strength creates cancer-killing effector cells, while too little or too much stimulation leads to exhaustion.
Researchers at TUM have uncovered a mechanism by which tumor cells prevent the formation of immune responses, including cytotoxic T cells. This discovery provides rationales for new cancer immunotherapies and could enhance existing treatments.
Researchers have identified CAR-T cell therapy as a potential treatment for autoimmune diseases such as rheumatoid arthritis, SLE, and type 1 Diabetes Mellitus. Early studies have shown promising results in reducing disease activity and improving patients' quality of life, but long-term data on safety and efficacy is limited.
Researchers have identified a subset of T-cells that acts like stem cells and continuously generates effector T-cells that attack transplanted organs. Targeting the transcription factor IRF4 may lead to innovative therapies for patients with chronic infections, cancers, autoimmune diseases and transplanted organs.
Researchers found that T cells can reshape their memory and maintain diversity against COVID-19 variants in response to successive mRNA vaccinations. The study revealed a shift among clonotypes, with a change from early responders to main responders after the second shot, suggesting a new dominant population of effector-memory T cells.
Scientists from the La Jolla Institute for Immunology found that patients with 'cold' tumors produce cancer-fighting T cells, suggesting a potential cure from within. The researchers developed an approach called 'Identify, Predict, Validate' to detect these T cells in over 130 patients.
The review highlights how T cell metabolism influences their fate, particularly in response to pathogen infections and tumorigenesis. It explores the role of glucose, fatty acids, and amino acids in energy production and metabolic adaptation, which can contribute to T cell exhaustion.
In a mouse model of multiple system atrophy, alpha-synuclein overexpression induces neuroinflammation, demyelination, and neurodegeneration. IFNγ produced by infiltrating CD4+ T-cells mediates these changes. The study suggests that IFNγ is a potential future disease-modifying therapeutic target.
Researchers have discovered that immune cells can form memories of pathogens at multiple phases during an infection, with the ability to switch between memory and effector cell fates. This flexibility enables individuals to better adapt to uncertain situations and respond effectively to different threats.
The Xue lab has made significant discoveries about the protein Tle3 and its role in regulating central memory T cells. By releasing Tle3's regulation, researchers were able to accelerate the formation of central memory T cells, leading to a more robust immune response.
Researchers from Tokyo Medical and Dental University have identified PD-1+ T cells as the culprit behind harmful inflammation in certain muscular disorders. The study found that these cells, when activated, produce cell-damaging molecules, causing body-wide weakness and pain.
Researchers identify memory CD8 T cells as potential therapeutic targets for atherosclerosis in aging. The study shows that these immune cells enhance plaque buildup in the arteries of aged mice, which could lead to heart attacks and strokes.
Researchers at UCLA have developed a new method to engineer more powerful immune cells that can potentially be used for 'off-the-shelf' cell therapy to treat challenging cancers. Gamma delta T cells with high expressions of CD16 surface marker exhibited increased ability to recognize and kill cancer cells.
Salk researchers identify Foxp3 as the protein that determines regulatory T cell genome structure and fate, enabling manipulation to treat autoimmunity or fight cancer. The study reveals Foxp3's essential role in creating unique chromatin architecture of regulatory T cells.
A research team at the Wyss Institute engineered a 3D model of extracellular matrix to study the impact of tissue mechanics on T cells. They found that viscoelasticity played a crucial role in shaping T cell traits and functions, enabling the creation of functionally distinct T cell populations for adoptive therapies.
Researchers discover cBAF protein complex plays crucial role in controlling T cell fate during infection. The study reveals how chromatin remodeling and genetic code accessibility influence the development of cytotoxic T cells into effector and memory subtypes.
A study found that patients with atopic dermatitis have a higher proportion of proinflammatory effector T cells and lower suppressive Tregs specific to a particular mite antigen, leading to the development of atopic symptoms.
Researchers developed a method to 'tip the balance' of immune cells from bad to good, reversing MS-like symptoms in 100% of mice and achieving full recovery in 38%. The therapy uses biodegradable microparticles to deliver three key therapeutic agents, including rapamycin and a myelin peptide.
Researchers at UCLA Jonsson Comprehensive Cancer Center have found a potential therapeutic target, IL-21, to reduce endocrine autoimmune side effects from checkpoint immunotherapy. A specific group of immune cells play a central role in this autoimmune attack and blocking IL-21 prevents thyroid autoimmunity.
Research at IRB Barcelona reveals CPEB4's essential role in T lymphocytes' adaptation to chronic cellular stress. By overcoming this stress, these cells can exert their antitumour function and halt tumour growth.
Regulatory T cells suppress self-reactive T cells by controlling protein synthesis, maintaining immune tolerance and preventing autoimmunity. A small molecule inhibitor called RocA also shows promise in mitigating inflammatory responses.
Researchers have discovered a way to predict the course of ALS by measuring immune cells in cerebrospinal fluid. A high proportion of effector T cells is associated with low survival rates, while activated regulatory T cells indicate a protective role against rapid disease progression.
The study found that protein kinase CK2 plays a key role in regulating CD8+ T cell activation, metabolic reprogramming and differentiation during infection by the intracellular pathogen Listeria monocytogenes. In mouse models, deletion of the CK2α catalytic subunit impaired CD8+ T cell function.
Researchers have developed a pioneering gene editing strategy that can repair faulty genes in immune cells, offering new hope for patients with conditions like CTLA-4 insufficiency. The technique uses CRISPR/Cas9 to target and correct the faulty gene, preserving important regulatory mechanisms.
Researchers captured first image of antigen-bound T-cell receptor complex with bound antigen at atomic resolution. The study reveals no significant structural changes in the receptor after antigen binding, sparking further investigation into the signaling pathway activation mechanism.
Researchers from Mount Sinai found a significant connection between the immune system and amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease. The study analyzed mice and human samples using state-of-the-art technologies, revealing peculiar immune signatures that distinguish different forms of ALS.
Researchers discovered that checkpoint inhibitors can activate regulatory T cells, which can counteract the immune response. Blocking PD-L1 enhanced effector Treg activity, reducing ability to control parasite infections. This finding highlights complexity of immune system's balance between controlling pathogens and protecting healthy ...
Researchers found that interleukin-2 promotes the development of two subsets of CD8 T cells, one producing IL-2 and the other not, with distinct fates. The IL-2-producing cells develop into immune memory cells with long-term protection, while the non-IL-2-producing cells gain effector traits but lose memory formation.
Scientists have identified the transcription factor Blimp1 as a new critical regulator of tumor-infiltrating regulatory T cells. Disrupting Blimp1 in these cells remodels the tumor microenvironment and augments the response to immunotherapy, promoting improved tumor control and anti-tumor immunity.
A recent UCI-led study reveals that cancer immunotherapy can trigger both favorable and unfavorable immune effects, with T regulatory cells playing a key role in limiting tumor control. The study found that CTLA-4 blockage activates these cells, decreasing the efficacy of immunotherapy and potentially leading to fatal autoimmunity.
Scientists at St. Jude Children's Research Hospital studied enhancers that regulate Foxp3 gene expression to control effector and killer T cells. They found that these enhancers work together to curb the immune cells' activity, ensuring they only attack cancer cells.
Immunologists at St. Jude Children's Research Hospital have mapped the biological machinery that generates T cells to kill bacteria, viruses, and tumor cells. The study reveals mechanisms that inhibit development of long-lived memory T cells, which can be blocked with pharmacological or genetic approaches to boost protective immunity.
Researchers at Technical University of Munich found that memory T cells form earlier in the immune response than previously believed, contrary to current scientific opinion. This discovery has significant implications for vaccine development and could lead to improved vaccines with increased long-term effectiveness.
Researchers have developed a therapy using engineered T cells to target and treat type 1 diabetes by restoring balance in the pancreas. The treatment involves genetically engineering a patient's own T cells to function like normal regulatory T cells, which then help suppress the overactive immune response.
Researchers have uncovered the intricate details of interleukin-2's interactions with receptor molecules, providing a blueprint for more targeted therapies. The study shows how IL-2 can act as either a throttle or a brake on the immune response in different contexts.
Researchers analyzed pleural effusion fluid from patients with non-small cell lung cancer and malignant mesothelioma, discovering unique cytokine profiles that may influence the tumor environment. The study suggests harnessing the local pleural immune environment could lead to improved treatment outcomes.
Researchers analyzed pleural effusions from NSCLC patients, mesothelioma, and benign cases, identifying distinct cytokine levels that may influence tumor growth and immune response. The study suggests modifying the local pleural immune environment with antibody-based therapeutics could enhance anti-tumor effects.
A new study from Penn researchers reveals that the molecular mechanisms of newly formed precursor T cells drive transformation into exhausted T cells. The discovery could help identify patients who may benefit from specific treatments, such as checkpoint inhibitors.
Research found that T-cells dominate advanced plaques and a subtype of T-cells, called CD4-positive effector memory cells, are more common in patients who have previously had a stroke or mini-stroke. This localized inflammation may be targeted by new immune therapies to reduce heart attack and stroke risk.
A specific transcription factor called JunB helps control the activity of effector regulatory T cells, which suppress immune activity. Without JunB regulation, mice develop severe inflammation in their lungs and colons, suggesting JunB prevents autoimmunity in specific organs.
Researchers at the University of Alabama at Birmingham have described a key immune response mechanism that determines the fate of T cells. This knowledge can aid in the development of better vaccines, treatments for infections, and moderation of autoimmune diseases.
Researchers discovered that regulatory T-cells can inhibit the activity of telomerase in effector lymphocytes, causing telomere loss and cell death. This mechanism, based on physiological ageing of immune cells, has potential for treating autoimmune diseases and preventing implant rejection.
Researchers at Gladstone Institutes discovered how to improve the survival of CD8 T cells, which can combat tumors and chronic infections. The study found that deleting two specific molecules enhances the survival of effector cells and yields more protective memory cells.
A new article explores the role of inflammatory cytokines in creating T cell exhaustion in cancer, suggesting a direct pathway for therapeutic interventions. The study found that reprogramming exhausted T cells and anti-inflammation therapy may improve antitumor activity.